Subject: FW: Recommended Article from Journal of Hepatology
From: Robert Gish <[email-masked]>
Date: Thu, 10 Oct 2019 09:41:33 +0000

I still treat HCV immediately when HCC and HCV are diagnosed simultaneously or there has been a delay in HCV therapy initiation

Why :?

Better QOL

Better renal function

Better liver function, with improvement in bilirubin, direct, albumin, portal hypertension

Better tolerance of HCC therapies whether it is ablative or systemic therapy

If the HCV relapses: treat again, the second course may have a PI and better liver function allows broader choice of DAA therapy for round 2

The data that one should wait to treat HCV until HCC is ablated is weak and the benefits outweigh the risks in my opinion

Thank you

RGG

From: Robert Gish

Sent: Sunday, September 29, 2019 7:39 PM

To: Robert Gish

Subject: Recommended Article from Journal of Hepatology

Article Citation

Article Title

Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis

Authors

Fanpu Ji, Yee Hui Yeo, Mike Tzuhen Wei, Eiichi Ogawa, Masaru Enomoto, Dong Hyun Lee, Etsuko Iio, John Lubel, Wenjun Wang, Bin Wei, Tatsuya Ide, Carmen Monica Preda, Fabio Conti, Tatsuya Minami,
Rob Bielen, Hitomi Sezaki, Michele Barone, Philippe Kolly, Po-sung Chu, Victor Virlogeux, Dennis Eurich, Linda Henry, Michelle B. Bass, Takanori Kanai, Shuangsuo Dang, Zongfang Li, Jean-François Dufour, Fabien Zoulim, Pietro Andreone, Ramsey C. Cheung, Yasuhito
Tanaka, Norihiro Furusyo, Hidenori Toyoda, Akihiro Tamori, Mindie H. Nguyen

Source

Journal of Hepatology - Sep 01, 2019

71|3|Pages 473-485

DOI: 10.1016/j.jhep.2019.04.017

DOI:
https://doi.org/10.1016/j.jhep.2019.04.017

September, 2019 | Volume 71 | Issue 3

© 2019 European Association for the Study of the Liver

Sent from my iPad